Cargando…

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients

To determine whether isotype matched immunoglobulin (Ig; Ig′κ/Ig′λ) ratios had prognostic significance in patients with intact Ig multiple myeloma (MM). Novel immunoassays measuring serum concentrations of the Ig heavy chain/light chain (HLC) subsets IgGκ, IgGλ, IgAκ and IgAλ were compared with mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradwell, A, Harding, S, Fourrier, N, Mathiot, C, Attal, M, Moreau, P, Harousseau, J-L, Avet-Loiseau, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542628/
https://www.ncbi.nlm.nih.gov/pubmed/22699454
http://dx.doi.org/10.1038/leu.2012.159
_version_ 1782255549657645056
author Bradwell, A
Harding, S
Fourrier, N
Mathiot, C
Attal, M
Moreau, P
Harousseau, J-L
Avet-Loiseau, H
author_facet Bradwell, A
Harding, S
Fourrier, N
Mathiot, C
Attal, M
Moreau, P
Harousseau, J-L
Avet-Loiseau, H
author_sort Bradwell, A
collection PubMed
description To determine whether isotype matched immunoglobulin (Ig; Ig′κ/Ig′λ) ratios had prognostic significance in patients with intact Ig multiple myeloma (MM). Novel immunoassays measuring serum concentrations of the Ig heavy chain/light chain (HLC) subsets IgGκ, IgGλ, IgAκ and IgAλ were compared with monoclonal protein (‘M-spike') quantification by serum protein electrophoresis, β(2)-microglobulin (β(2)-M), albumin, serum free light chain (FLC) and cytogenetic markers in relation to outcome in 339 MM patients. Abnormal IgGκ/IgGλ and IgAκ/IgAλ ratios present in the respective tumor isotypes at clinical presentation were predictive of shorter progression-free survival (PFS) (hazard ratio (HR) 1.9; P=0.0002), predominantly due to the suppression of the uninvolved (polyclonal) Ig of the same isotype as the tumor (HR 1.8; P=0.002). No significant associations were observed between PFS and M-spike concentrations, suppression of non-tumor Igs of different isotypes or FLC κ/λ ratios. β(2)-M and HLC ratios were independently prognostic (P=0.045 and P=0.001). A staging system using β(2)-M and extreme HLC ratios (<0.01 or >200) had greater prognostic value than the widely used ISS staging system (HR 1.7; P=0.00002 vs HR 1.3; P=0.017). These results suggest that HLC ratios may have a role in clinical management of MM.
format Online
Article
Text
id pubmed-3542628
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35426282013-01-11 Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients Bradwell, A Harding, S Fourrier, N Mathiot, C Attal, M Moreau, P Harousseau, J-L Avet-Loiseau, H Leukemia Original Article To determine whether isotype matched immunoglobulin (Ig; Ig′κ/Ig′λ) ratios had prognostic significance in patients with intact Ig multiple myeloma (MM). Novel immunoassays measuring serum concentrations of the Ig heavy chain/light chain (HLC) subsets IgGκ, IgGλ, IgAκ and IgAλ were compared with monoclonal protein (‘M-spike') quantification by serum protein electrophoresis, β(2)-microglobulin (β(2)-M), albumin, serum free light chain (FLC) and cytogenetic markers in relation to outcome in 339 MM patients. Abnormal IgGκ/IgGλ and IgAκ/IgAλ ratios present in the respective tumor isotypes at clinical presentation were predictive of shorter progression-free survival (PFS) (hazard ratio (HR) 1.9; P=0.0002), predominantly due to the suppression of the uninvolved (polyclonal) Ig of the same isotype as the tumor (HR 1.8; P=0.002). No significant associations were observed between PFS and M-spike concentrations, suppression of non-tumor Igs of different isotypes or FLC κ/λ ratios. β(2)-M and HLC ratios were independently prognostic (P=0.045 and P=0.001). A staging system using β(2)-M and extreme HLC ratios (<0.01 or >200) had greater prognostic value than the widely used ISS staging system (HR 1.7; P=0.00002 vs HR 1.3; P=0.017). These results suggest that HLC ratios may have a role in clinical management of MM. Nature Publishing Group 2013-01 2012-08-03 /pmc/articles/PMC3542628/ /pubmed/22699454 http://dx.doi.org/10.1038/leu.2012.159 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Bradwell, A
Harding, S
Fourrier, N
Mathiot, C
Attal, M
Moreau, P
Harousseau, J-L
Avet-Loiseau, H
Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title_full Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title_fullStr Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title_full_unstemmed Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title_short Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
title_sort prognostic utility of intact immunoglobulin ig′κ/ig′λ ratios in multiple myeloma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542628/
https://www.ncbi.nlm.nih.gov/pubmed/22699454
http://dx.doi.org/10.1038/leu.2012.159
work_keys_str_mv AT bradwella prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT hardings prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT fourriern prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT mathiotc prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT attalm prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT moreaup prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT harousseaujl prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients
AT avetloiseauh prognosticutilityofintactimmunoglobulinigkiglratiosinmultiplemyelomapatients